Interpace Biosciences, Inc. IDXG
Nov 4, 2026, 1:17 PM EST
- YTD
- +365.04%
- 1 year
- +483.67%
- Market cap
- 33.76M
- Revenue (ttm)
- 26.83M
- Profit margin
- -107.95%
- EPS (ttm)
- 4.50
- Shares out
- 4.06M
- P/E ratio
- 1.27
- Forward P/E
- -2.02
- YTD return
- +365.04%
- 1-year return
- +483.67%
- Volume
- 830
- Avg volume
- 4.23K
- Open
- 5.50
- Previous close
- 5.35
- Day's range
- 5.50 – 5.72
- 52-week range
- 0.806 – 7.80
- Beta
- 0.95
- Analysts
- Buy
- Price target
- 8.43 (+47.4%)
3M +3.81 (+233.74%)
Key statistics
- Enterprise value
- 63.41M
- PEG ratio
- -0.05
- Price / sales
- 0.59
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 6.80%
- Free cash flow
- -8.33M
- Total cash
- 5.31M
- Total debt
- 5.02M
- Return on equity
- -93.43%
- Short % of float
- 0.74%
- 50-day average
- 4.46
- 200-day average
- 3.68
Analyst view
Consensus: buy
- Target (low)
- 6.00
- Target (mean)
- 8.43
- Target (high)
- 12.00
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -1.15.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2024 | Sep 1, 2024 | 0.00 | 0.31 | — | — |
| Aug 2, 2024 | Jun 1, 2024 | 0.00 | 0.48 | — | — |
| May 9, 2024 | Mar 1, 2024 | 0.00 | 0.13 | — | — |
| Nov 8, 2023 | Sep 1, 2023 | 0.00 | -0.12 | — | — |
| Aug 9, 2023 | Jun 1, 2023 | 0.00 | 0.09 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 24, 2021 | HC Wainwright & Co. | main | — | Buy |
| Oct 21, 2020 | HC Wainwright & Co. | main | — | Buy |
| Jun 25, 2020 | HC Wainwright & Co. | main | — | Buy |
| Apr 22, 2020 | H.C. Wainwright | main | — | Buy |
| Apr 14, 2020 | Janney Capital | init | — | Buy |
| Jan 15, 2020 | Oppenheimer | main | — | Outperform |
About Interpace Biosciences, Inc.
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- wearepdi.com
News
Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue 
Interpace Biosciences (OTCMKTS:IDXG) Shares Up 351.4% – Time to Buy? 
Interpace Biosciences Announces Reverse Stock Split to Support Proposed Nasdaq Uplisting 
Critical Contrast: Interpace Biosciences (OTCMKTS:IDXG) versus Ethema Health (OTCMKTS:GRST) 
Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results 
Interpace Biosciences Announces First Quarter 2026 Financial and Business Results 
Head to Head Contrast: Retractable Technologies (NYSE:RVP) & Interpace Biosciences (OTCMKTS:IDXG) 
Head to Head Analysis: Dynatronics (NASDAQ:DYNT) versus Interpace Biosciences (OTCMKTS:IDXG) 
Interpace Biosciences (OTCMKTS:IDXG) Stock Crosses Above 200-Day Moving Average – Here’s What Happened 
Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results
Your note
Sign in to keep a note on IDXG — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BURNELL THOMAS W. PH.D. | Chief Executive Officer | Stock Award(Grant) | Nov 30, 2020 | 225,000 |
| EARLY JAMES | Former | Conversion of Exercise of derivative security | Jul 28, 2020 | 7,125 |
| FREEBURG THOMAS JOHN | Officer | Stock Award(Grant) | Mar 12, 2019 | 2,000 |
| GORMAN ROBERT J. | Director | Stock Award(Grant) | Jan 28, 2021 | 18,759 |
| KEEGAN JOSEPH D | Director | Stock Award(Grant) | Mar 6, 2018 | 17,569 |
| LAMPE-ONNERUD CHRISTINA | Director | Stock Award(Grant) | Jan 30, 2020 | 2,391 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 2.89% | 117,154 | 367.86K | Dec 30, 2020 |
| Vanguard Group, Inc. (The) | 1.99% | 80,612 | 253.12K | Dec 30, 2020 |
| Geode Capital Management, LLC | 0.80% | 32,476 | 101.97K | Dec 30, 2020 |
| Squarepoint Ops LLC | 0.51% | 20,755 | 65.17K | Dec 30, 2020 |
| Dimensional Fund Advisors LP | 0.32% | 12,864 | 40.39K | Dec 30, 2020 |
| UBS Group AG | 0.07% | 2,946 | 9.25K | Dec 30, 2020 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.78% | 31,834 | 98.37K | Sep 29, 2020 |
| Vanguard Total Stock Market Index Fund | 0.65% | 26,365 | 81.47K | Sep 29, 2020 |
| Fidelity Extended Market Index Fund | 0.43% | 17,441 | 54.76K | Dec 30, 2020 |
| Fidelity NASDAQ Composite Index Fund | 0.17% | 6,839 | 21.47K | Dec 30, 2020 |
| Fidelity Total Market Index Fund | 0.14% | 5,524 | 17.34K | Dec 30, 2020 |
| DFA U.S. Micro Cap Series | 0.13% | 5,404 | 18.86K | Oct 30, 2020 |